A5031502331- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Long-Term Effects of COVID-19
- Systemic Sclerosis and Related Diseases
- Inflammasome and immune disorders
- Diet, Metabolism, and Disease
- Salivary Gland Disorders and Functions
- Bone and Joint Diseases
- Spondyloarthritis Studies and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Diet and metabolism studies
- Viral Infections and Immunology Research
- SARS-CoV-2 and COVID-19 Research
- Inflammatory Myopathies and Dermatomyositis
- Psoriasis: Treatment and Pathogenesis
- Lymphoma Diagnosis and Treatment
- Nutrition and Health in Aging
- Sepsis Diagnosis and Treatment
- Dermatology and Skin Diseases
- Gout, Hyperuricemia, Uric Acid
- Otitis Media and Relapsing Polychondritis
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2024
Policlinico San Matteo Fondazione
2010-2024
University of Pavia
1985-2021
Azienda Socio Sanitaria Territoriale Lariana
2020
Azienda Ospedaliera Ospedale Maggiore
1999
A cohort of rheumatoid arthritis (RA) patients in the Lombardy Rheumatology Network (LOHREN) registry and receiving anti‐TNF therapy was evaluated after 6, 12, 24, 36 months. Of 1114 1064 met clinical criteria for inclusion with 519 infliximab, 303 adalimumab, 242 etanercept. The therapeutic survival curve these showed that likelihood continuing 78.8% 12 months, 65.2% 24 52.9% a risk dropout similar inefficacy adverse events. There were 405 discontinuations (38.1%): 180 (16.9%) due to...
Background To assess whether, in the real world of three early arthritis clinics, referral could allow best outcome, ie, remission, to be reached, and whether reaching outcome was more dependent on therapy than disease duration or vice versa. Methods 1795 patients with (symptom ≤12 months) were entered into a prospective follow-up study. 711 (39.6%) diagnosed rheumatoid (RA). Each RA patient treated according local algorithm, tertiary centres (representing small province, medium sized...
The aim of the present study was to investigate effect long-term infliximab treatment on various autoantibodies in patients with rheumatoid arthritis. Serum samples from 30 consecutive patients, who were prospectively followed during and methotrexate therapy for refractory arthritis, tested at baseline after 30, 54 78 weeks. At these points, median values Disease Activity Score 6.38 (interquartile range 5.30-6.75), 3.69 (2.67-4.62), 2.9 (2.39-4.65) 3.71 (2.62-5.06), respectively. Various...
To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (anti-CCP) antibodies are related to clinical response in patients with arthritis treated tumour necrosis alpha (TNFalpha) inhibitors.The study was carried out on 132 advanced refractory disease-modifying antirheumatic drugs. Patients were infliximab (n = 63), etanercept 35) or adalimumab 34). All completed 1 year of follow-up, 126 evaluable for according the disease activity score (DAS) criteria. IgM,...
To assess the safety of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy on course hepatitis B virus (HBV) infection in carriers antibodies to core antigen (anti-HBc) affected by chronic inflammatory arthropathies.From January 2001 December 2008, HBV markers were determined before first administration anti-TNFalpha agents all 732 patients arthropathies treated with at 2 outpatient rheumatologic clinics Northern Italy. Anti-HBc-positive prospectively evaluated and DNA assessed every 6...
To analyze the safety of our biopsy technique and effectiveness minor salivary gland (MSGB) for diagnosis Sjögren's syndrome (SS) amyloidosis.We conducted a retrospective analysis 452 patients with suspected SS 50 amyloidosis negative periumbilical fat aspiration who underwent MSGB at single center. Diagnostic evaluation included Schirmer's test, unstimulated whole flow, detection antinuclear antibodies anti-SSA/SSB, erythrocyte sedimentation rate, C-reactive protein, IgM rheumatoid factor,...
The outburst of the novel COVID-19 has caused unprecedented stress in healthcare systems and global economy since its outbreak December 2019.Effective treatment for severely ill patients still needs to be identified, many countries are pushed by daily increases case numbers deaths.Furthermore, before a vaccine is made available or drugs eventually capable preventing infection exit strategies those that have managed bend transmission curve inevitably governed trial error.The alarm remains...
Abstract Background Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim the study is investigate impact glucocorticoids immunosuppressive agents on COVID-19 a large cohort patients with chronic immune-mediated inflammatory arthritis. Methods was conducted arthritis outpatient clinic at two academic hospitals most endemic area Northern Italy (Lombardy). We circulated cross-sectional survey exploring prevalence severe...
Abstract Introduction The purpose of this study was to investigate the prevalence cyclic citrullinated peptide antibodies (anti-CCP) in patients with primary Sjögren syndrome (pSS) and its correlation clinical laboratory data. Methods We analysed serological data 155 consecutive pSS. Among these, 14 were excluded due fulfillment American College Rheumatology criteria for rheumatoid arthritis (RA). So, 141 (27 males 114 females; mean age 48 years, range 39 60) clinically assessed presence...
To find out whether a high number of auto-antibodies can increase the probability "good-EULAR response" and to identify possible biomarkers response in seropositive rheumatoid arthritis (RA) patients undergoing B cell depletion therapy (BCDT).One hundred thirty-eight with long standing RA (LSRA), 75% non or poorly responsive one more TNFα blockers, all for at least autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received full course BCDT. The major...
Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic (DMARDs) (1-4). At about the same time as European approval of third anti-TNFα agent (adalimumab) for treating RA patients, Italian Society Rheumatology (Società Italiana di Reumatologia [SIR]) started a database registration and active follow-up treated biological response modifiers, which contains all demographic...